Centogene N.V. is a global biopharmaceutical research and diagnostics company that specializes in the field of rare genetic diseases. The primary function of Centogene is to provide genetic testing and diagnostics to accelerate the discovery, development, and availability of new treatments for these rare conditions. By combining clinical, genetic, and multi-omics data, Centogene aims to address the unmet medical needs across multiple genetic disorders.

The company significantly impacts the healthcare and biotechnology sectors by facilitating personalized medicine and precision diagnostics. Centogene's comprehensive database, which includes epidemiological and clinical data, is a crucial resource for pharmaceutical and biopharmaceutical companies engaged in the development of targeted therapies. The company's efforts in rare disease diagnostics also serve hospitals, research institutions, and individual healthcare providers.

Centogene N.V.'s role in the financial market is centered around its potential contributions to medical advancements and partnerships with drug developers. Its innovations in genetic testing and data-driven research have positioned it as a pivotal entity in progressing the understanding and treatment of genetic disorders on a global scale.